Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 1:ciaf425.
doi: 10.1093/cid/ciaf425. Online ahead of print.

Long-acting cabotegravir/rilpivirine, lenacapavir, and ibalizumab use among persons with HIV-1 viremia at a Ryan White-funded clinic in the urban U.S. South

Jonathan A Colasanti  1   2   3 , Amalia Aldredge  1   2 , Larisa V Niles-Carnes  1 , Eudiah Ochieng  1 , Priyasha Pareek  2 , Vickie Robinson  1 , Erica Anderson  1 , Mary Castaneda  1 , Hilary Spralling  1 , Bradley L Smith  1 , Jeri Sumitani  1 , Eric Paul Leue  1 , Caitlin A Moran  1   2 , Meredith Lora  1   4 , Wendy S Armstrong  1   2 , Lauren F Collins  1   2
Affiliations

Long-acting cabotegravir/rilpivirine, lenacapavir, and ibalizumab use among persons with HIV-1 viremia at a Ryan White-funded clinic in the urban U.S. South

Jonathan A Colasanti et al. Clin Infect Dis. .

Abstract

Background: People with HIV (PWH) with viremia despite oral antiretroviral therapy (ART) can achieve viral suppression (VS) using long-acting (LA)-ART. Scaling this approach has lagged, especially in highest HIV burden areas.

Methods: We performed a retrospective review of PWH who initiated LA-ART (cabotegravir/rilpivirine [CAB/RPV] ± lenacapavir [LEN] ± ibalizumab [IBA]) with viremia (≥50 c/mL) at a Ryan White-funded program in the urban South between 4/14/2021-8/31/2024. Among PWH who received ≥3 LA-CAB/RPV injections through end of follow-up (12/31/2024), achieving VS (<50 c/mL) was assessed.

Results: 81 PWH with viremia initiated LA-ART. 93% identified as Black, 40% were cis/trans-women, median (Q1-Q3) age was 38 (30-49) years and income $25K/yr ($20-33K/yr). Median (Q1-Q3) years since HIV diagnosis was 15.5 (8.8-20.5) and 46% had prior opportunistic conditions. At LA-ART initiation (56 CAB/RPV; 22 CAB±RPV+LEN; 3 CAB±RPV+LEN+IBA), median (Q1-Q3) viral load was 4.0 (2.9-4.8) log10 and CD4+ 186 (62-420) cells/μL. Of 79 PWH who remained engaged, 73 (92%) achieved VS after a median (Q1-Q3) of one (1-2) injection, with CD4 rise to 353 (187-501) cells/μL. Otherwise, two had virologic failure with drug resistance; four had persistent viremia without resistance (>200 c/mL [n=2]; 50-200 c/mL [n=2]). Of 645 LA-CAB/RPV injections (500 Q4wk; 145 Q8wk), 635 (98%) were administered on-time; all LEN (43/43) and IBA (37/37) administrations occurred on-time.

Conclusions: In the largest Southern US cohort of PWH with viremia initiating LA-ART, 92% achieved VS despite significant barriers to care and disease burden, underscoring LA-ART as a tool to help achieve Ending the HIV Epidemic goals.

Keywords: Southern HIV/AIDS epidemic; cabotegravir/rilpivirine; ibalizumab; lenacapavir; long-acting injectable antiretroviral therapy; multidrug resistance; persons with HIV-1 viremia.

PubMed Disclaimer